Literature DB >> 26968994

Moderate vasomotor response to acetylcholine provocation test as an indicator of long-term prognosis.

Masahiro Hoshino1, Taishi Yonetsu2, Akira Mizukami2, Yuji Matsuda2, Kenji Yoshioka2, Yuta Sudo2, Ryo Ninomiya2, Masao Soeda2, Shunsuke Kuroda2, Maki Ono2, Ryota Iwatsuka2, Makoto Suzuki2, Akihiko Matsumura2, Yuji Hashimoto2.   

Abstract

The acetylcholine (ACh) provocation test (ACh-test) is used for the diagnosis of vasospastic angina (VSA). However, subjects often show a moderate spasm (MS) response for which diagnosis of VSA is not definitive, and the clinical significance of this response is unknown. We assessed moderate coronary vasomotor response to the ACh test as an indicator of long-term prognosis. A total of 298 consecutive patients who underwent the ACh test for suspected VSA were retrospectively investigated. Coronary spasm severity after intracoronary administration of isosorbide dinitrate was evaluated by measuring epicardial coronary artery diameter reduction after ACh injection. Patients were divided into three groups according to the diameter reduction during the ACh test: severe spasm (SS) showing ≥75 % diameter reduction, MS showing ≥50 % diameter reduction, and others (N). In Kaplan-Meier analysis, the major adverse cardiac event (MACE) rates with a median follow-up of 4.6 years were significantly worse in SS (11.1 %) and MS (8.5 %) than N (1.9 %), (SS vs N; P = 0.009, MS vs N; P = 0.029). Significant difference in MACE rates was not observed between SS and MS (P = 0.534). Cox regression analysis revealed that MS remained an independent predictor of MACE after adjustment for other confounders (HR: 7.18, 95 % CI 1.42-36.4, P = 0.017). Patients with MS by ACh test had a cardiac event rate comparable with that of patients with SS and significantly worse than that of patients with normal vasomotor responses.

Entities:  

Keywords:  Acetylcholine; Endothelial dysfunction; Prognosis; Spasm

Mesh:

Substances:

Year:  2016        PMID: 26968994     DOI: 10.1007/s00380-016-0827-9

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  30 in total

1.  Safety and optimal protocol of provocation test for diagnosis of multivessel coronary spasm.

Authors:  Shozo Sueda; Toru Miyoshi; Yasuhiro Sasaki; Tomoki Sakaue; Hirokazu Habara; Hiroaki Kohno
Journal:  Heart Vessels       Date:  2014-11-01       Impact factor: 2.037

2.  Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects.

Authors: 
Journal:  Am J Cardiol       Date:  2004-04-15       Impact factor: 2.778

3.  Mild stenosis makes prognosis of vasospastic angina worse.

Authors:  Fumimaro Takatsu; Masato Watarai
Journal:  Coron Artery Dis       Date:  2011-01       Impact factor: 1.439

4.  Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction.

Authors:  J A Suwaidi; S Hamasaki; S T Higano; R A Nishimura; D R Holmes; A Lerman
Journal:  Circulation       Date:  2000-03-07       Impact factor: 29.690

5.  Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure.

Authors:  B Hornig; N Arakawa; D Haussmann; H Drexler
Journal:  Circulation       Date:  1998 Dec 22-29       Impact factor: 29.690

6.  Long-term prognosis for patients with variant angina and influential factors.

Authors:  H Yasue; A Takizawa; M Nagao; S Nishida; M Horie; J Kubota; S Omote; K Takaoka; K Okumura
Journal:  Circulation       Date:  1988-07       Impact factor: 29.690

7.  Flow-mediated, endothelium-dependent dilatation of the brachial arteries is impaired in patients with coronary spastic angina.

Authors:  T Motoyama; H Kawano; K Kugiyama; K Okumura; M Ohgushi; M Yoshimura; O Hirashima; H Yasue
Journal:  Am Heart J       Date:  1997-03       Impact factor: 4.749

8.  Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries.

Authors:  Peter Ong; Anastasios Athanasiadis; Gabor Borgulya; Ismail Vokshi; Rachel Bastiaenen; Sebastian Kubik; Stephan Hill; Tim Schäufele; Heiko Mahrholdt; Juan Carlos Kaski; Udo Sechtem
Journal:  Circulation       Date:  2014-02-26       Impact factor: 29.690

9.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients.

Authors:  E Antman; J Muller; S Goldberg; R MacAlpin; M Rubenfire; B Tabatznik; C S Liang; F Heupler; S Achuff; N Reichek; E Geltman; N Z Kerin; R K Neff; E Braunwald
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

10.  Progression of coronary atherosclerosis: is coronary spasm related to progression?

Authors:  M Nobuyoshi; M Tanaka; H Nosaka; T Kimura; H Yokoi; N Hamasaki; K Kim; T Shindo; K Kimura
Journal:  J Am Coll Cardiol       Date:  1991-10       Impact factor: 24.094

View more
  2 in total

1.  Paroxysmal atrial fibrillation during intracoronary acetylcholine provocation test.

Authors:  Yuichi Saito; Hideki Kitahara; Toshihiro Shoji; Satoshi Tokimasa; Takashi Nakayama; Kazumasa Sugimoto; Yoshihide Fujimoto; Yoshio Kobayashi
Journal:  Heart Vessels       Date:  2016-12-22       Impact factor: 2.037

Review 2.  Prevalence of Coronary Microvascular Disease and Coronary Vasospasm in Patients With Nonobstructive Coronary Artery Disease: Systematic Review and Meta-Analysis.

Authors:  Niya Mileva; Sakura Nagumo; Takuya Mizukami; Jeroen Sonck; Colin Berry; Emanuele Gallinoro; Giovanni Monizzi; Alessandro Candreva; Daniel Munhoz; Dobrin Vassilev; Martin Penicka; Emanuele Barbato; Bernard De Bruyne; Carlos Collet
Journal:  J Am Heart Assoc       Date:  2022-03-18       Impact factor: 6.106

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.